A new manuscript series – The Next Wave of Immuno-oncology: A
Roadmap from the Society for Immunotherapy of Cancer – outlines the
current state of the immunotherapy field, elevates the most
pressing challenges and proposes the promising opportunities for
high clinical impact in the scientific, clinical, and regulatory
arenas of cancer immunotherapy.
MILWAUKEE, June 24,
2024 /PRNewswire-PRWeb/ -- A new manuscript series –
The Next Wave of Immuno-oncology: A Roadmap from the Society for
Immunotherapy of Cancer – outlines the current state of the
immunotherapy field, elevates the most pressing challenges and
proposes the promising opportunities for high clinical impact in
the scientific, clinical, and regulatory arenas of cancer
immunotherapy.
"It has been exciting to reflect on how far
cancer immunotherapy has come and develop a framework to guide the
next decade of progress. This manuscript series is synergistic with
SITC's strategic vision and mission," said SITC President
Leisha Emens, MD, PhD.
The first manuscript of the series, "Challenges and
Opportunities in Cancer Immunotherapy: A Society for Immunotherapy
of Cancer (SITC) Strategic Vision," is available now in the Journal
for ImmunoTherapy of Cancer (JITC).
This series updates the landmark editorial published by SITC
leaders in 2011, "Defining the critical hurdles in cancer
immunotherapy." In the 13 years since that publication, cancer
immunotherapy has grown exponentially and completely transformed
cancer care. As we enter the next era of cancer immunotherapy, SITC
leadership recognized the importance of understanding the complex
and evolving landscape of old and new challenges that might hinder
the next wave of immuno-oncology approvals or further progress. To
support and galvanize the field, an international,
multidisciplinary group of cancer immunotherapy experts from
academic, pharmaceutical, biotechnology, patient advocacy, and
regulatory institutions was convened to redefine the most pressing
challenges today and high-impact opportunities to overcome
them.
"It has been exciting to reflect on how far cancer immunotherapy
has come and develop a framework to guide the next decade of
progress. This manuscript series is synergistic with SITC's
strategic vision and mission," said SITC President Leisha Emens, MD, PhD. "This overarching
manuscript briefly reviews the evolution of the field and looks to
future efforts by summarizing prioritized challenges and potent
opportunities to further accelerate progress. The manuscript also
serves as a call to action to address these critical challenges and
work towards overcoming them for the benefit of cancer patients
everywhere."
The first manuscript introduces the newly defined challenges and
areas of opportunity listed below by describing the state of the
field and needs, current challenges, and opportunities for
each:
- Mechanisms of anti-tumor immunity and toxicity
- Biomarker and biospecimen issues
- Unique aspects of novel constructs
- Host and environmental interactions with tumor
immunotherapy
- Pre-malignant immunity
- Clinical trial design, endpoints, and conduct
- Mechanisms of drug resistance
Additionally, to provide a roadmap for the field and catalyze
future successes, this overarching manuscript also includes
expert-identified strategies or tools that have the potential to be
cross-cutting through multiple areas of opportunity and have
significant clinical impact if implemented. Central to all the
opportunities and strategies discussed are the patients – this
manuscript highlights the importance of patient engagement at every
step of translational research and the ultimate goal of improving
outcomes and survival.
"I am honored to be part of bringing these manuscripts to life,"
commented Jennifer Wargo, MD,
co-chair of the SITC Challenges and Opportunities in Cancer
Immunotherapy author group. "I appreciate all of the manuscript
authors who contributed their time and expertise, our colleagues
who participated in SITC's 2023 Strategic Retreat where these
topics were discussed and defined, and the Society for their
support of this effort."
The forthcoming manuscripts in the JITC Special Series will take
a deeper dive into each area of opportunity described above. More
information on the special series can be found here.
About SITC
Established in 1984, the Society for Immunotherapy of Cancer (SITC)
is a nonprofit organization of medical professionals dedicated to
improving cancer patient outcomes by advancing the development,
science and application of cancer immunotherapy and tumor
immunology. SITC is comprised of influential basic and
translational scientists, practitioners, health care professionals,
government leaders and industry professionals around the globe.
Through educational initiatives that foster scientific exchange and
collaboration among leaders in the field, SITC aims to one day make
the word "cure" a reality for cancer patients everywhere. Learn
more about SITC, our educational offerings and other resources at
sitcancer.org and follow us on Twitter, LinkedIn, Facebook and
YouTube.
Media Contact
Thomas Martin, Society for
Immunotherapy of Cancer, 414-271-2456, tmartin@sitcancer.org,
sitcancer.org
Twitter LinkedIn
View original content to download
multimedia:https://www.prweb.com/releases/sitc-publishes-first-manuscript-in-jitc-special-series-on-the-current-challenges-and-opportunities-in-cancer-immunotherapy-302180435.html
SOURCE Society for Immunotherapy of Cancer